CA125 reduction as a potential predictive marker of radiological response to neoadjuvant chemotherapy in advanced unresectable endometrial cancer
Objective Neoadjuvant chemotherapy (NACT) followed by interval cytoreductive surgery is increasingly used in advanced endometrial cancer patients not amenable for primary surgery. However, validated biomarkers to predict treatment response and surgical outcomes remain lacking.
Authors
- Karen K. L. Chan (ORCID: https://orcid.org/0000-0002-4034-7469)
- Siew‐Fei Ngu (ORCID: https://orcid.org/0000-0001-9314-5468)
- Joshua Jing Xi Li (ORCID: https://orcid.org/0000-0003-2425-0314)
- Ka Yu Tse (ORCID: https://orcid.org/0000-0001-8330-0970)
- Wan Kam Chiu (ORCID: https://orcid.org/0009-0008-4602-2324)
- Philip P.C. Ip (ORCID: https://orcid.org/0000-0002-0493-9838)
- Hys Ngan (ORCID: https://orcid.org/0000-0003-3945-159X)
- Shuk Tak Kwok (ORCID: https://orcid.org/0000-0003-4544-8645)
- Any Cheung (ORCID: https://orcid.org/0000-0002-1584-7568)
- Benoît You (ORCID: https://orcid.org/0000-0002-3177-8857)
- Mandy Man Yee Chu (ORCID: https://orcid.org/0000-0002-1525-0147)
- Lesley Suk Kwan Lau
Institutions
- Queen Mary Hospital (CN)
- United Christian Hospital (CN)
- Hospices Civils de Lyon (FR)
- University of Hong Kong (HK)
Publication Details
- Journal
- Journal of Gynecologic Oncology
- Published
- 2026-11-18
- DOI
- https://doi.org/10.3802/jgo.2027.38.e59
- Primary Topic
- Endometrial and Cervical Cancer Treatments
- Type
- article
- Field-Weighted Citation Impact
- 0.00